Research ExplorerPublicationsCharacteristics and Clinical Outcome of Breast Cancer Patien...

Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases

Standard

Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. / Laakmann, Elena; Witzel, Isabell; Neunhöffer, Tanja; Weide, Rudolf; Schmidt, Marcus; Park-Simon, Tjoung-Won; Möbus, Volker; Mundhenke, Christoph; Polasik, Arkadius; Lübbe, Kristina; Hesse, Tobias; Riecke, Kerstin; Thill, Marc; Fasching, Peter A; Denkert, Carsten; Fehm, Tanja; Nekljudova, Valentina; Rey, Julia; Loibl, Sibylle; Müller, Volkmar.

In: CANCERS, Vol. 12, No. 10, 28.09.2020.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Laakmann, E, Witzel, I, Neunhöffer, T, Weide, R, Schmidt, M, Park-Simon, T-W, Möbus, V, Mundhenke, C, Polasik, A, Lübbe, K, Hesse, T, Riecke, K, Thill, M, Fasching, PA, Denkert, C, Fehm, T, Nekljudova, V, Rey, J, Loibl, S & Müller, V 2020, 'Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases', CANCERS, vol. 12, no. 10. https://doi.org/10.3390/cancers12102787

APA

Laakmann, E., Witzel, I., Neunhöffer, T., Weide, R., Schmidt, M., Park-Simon, T-W., Möbus, V., Mundhenke, C., Polasik, A., Lübbe, K., Hesse, T., Riecke, K., Thill, M., Fasching, P. A., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S., & Müller, V. (2020). Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. CANCERS, 12(10). https://doi.org/10.3390/cancers12102787

Vancouver

Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon T-W et al. Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. CANCERS. 2020 Sep 28;12(10). https://doi.org/10.3390/cancers12102787

Bibtex

@article{ea7657f9e7764eeb984439ca3493e1f1,
title = "Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases",
abstract = "Background: Brain metastases (BM) have become a major challenge in patients with metastatic breast cancer. Methods: The aim of this analysis was to characterize patients with asymptomatic BM (n = 580) in the overall cohort of 2589 patients with BM from our Brain Metastases in Breast Cancer Network Germany (BMBC) registry. Results: Compared to symptomatic patients, asymptomatic patients were slightly younger at diagnosis (median age: 55.5 vs. 57.0 years, p = 0.01), had a better performance status at diagnosis (Karnofsky index 80-100%: 68.4% vs. 57%, p < 0.001), a lower number of BM (>1 BM: 56% vs. 70%, p = 0.027), and a slightly smaller diameter of BM (median: 1.5 vs. 2.2 cm, p < 0.001). Asymptomatic patients were more likely to have extracranial metastases (86.7% vs. 81.5%, p = 0.003) but were less likely to have leptomeningeal metastasis (6.3% vs. 10.9%, p < 0.001). Asymptomatic patients underwent less intensive BM therapy but had a longer median overall survival (statistically significant for a cohort of HER2-positive patients) compared to symptomatic patients (10.4 vs. 6.9 months, p < 0.001). Conclusions: These analyses show a trend that asymptomatic patients have less severe metastatic brain disease and despite less intensive local BM therapy still have a better outcome (statistically significant for a cohort of HER2-positive patients) than patients who present with symptomatic BM, although a lead time bias of the earlier diagnosis cannot be ruled out. Our analysis is of clinical relevance in the context of potential trials examining the benefit of early detection and treatment of BM.",
author = "Elena Laakmann and Isabell Witzel and Tanja Neunh{\"o}ffer and Rudolf Weide and Marcus Schmidt and Tjoung-Won Park-Simon and Volker M{\"o}bus and Christoph Mundhenke and Arkadius Polasik and Kristina L{\"u}bbe and Tobias Hesse and Kerstin Riecke and Marc Thill and Fasching, {Peter A} and Carsten Denkert and Tanja Fehm and Valentina Nekljudova and Julia Rey and Sibylle Loibl and Volkmar M{\"u}ller",
year = "2020",
month = sep,
day = "28",
doi = "10.3390/cancers12102787",
language = "English",
volume = "12",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "10",

}

RIS

TY - JOUR

T1 - Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases

AU - Laakmann, Elena

AU - Witzel, Isabell

AU - Neunhöffer, Tanja

AU - Weide, Rudolf

AU - Schmidt, Marcus

AU - Park-Simon, Tjoung-Won

AU - Möbus, Volker

AU - Mundhenke, Christoph

AU - Polasik, Arkadius

AU - Lübbe, Kristina

AU - Hesse, Tobias

AU - Riecke, Kerstin

AU - Thill, Marc

AU - Fasching, Peter A

AU - Denkert, Carsten

AU - Fehm, Tanja

AU - Nekljudova, Valentina

AU - Rey, Julia

AU - Loibl, Sibylle

AU - Müller, Volkmar

PY - 2020/9/28

Y1 - 2020/9/28

N2 - Background: Brain metastases (BM) have become a major challenge in patients with metastatic breast cancer. Methods: The aim of this analysis was to characterize patients with asymptomatic BM (n = 580) in the overall cohort of 2589 patients with BM from our Brain Metastases in Breast Cancer Network Germany (BMBC) registry. Results: Compared to symptomatic patients, asymptomatic patients were slightly younger at diagnosis (median age: 55.5 vs. 57.0 years, p = 0.01), had a better performance status at diagnosis (Karnofsky index 80-100%: 68.4% vs. 57%, p < 0.001), a lower number of BM (>1 BM: 56% vs. 70%, p = 0.027), and a slightly smaller diameter of BM (median: 1.5 vs. 2.2 cm, p < 0.001). Asymptomatic patients were more likely to have extracranial metastases (86.7% vs. 81.5%, p = 0.003) but were less likely to have leptomeningeal metastasis (6.3% vs. 10.9%, p < 0.001). Asymptomatic patients underwent less intensive BM therapy but had a longer median overall survival (statistically significant for a cohort of HER2-positive patients) compared to symptomatic patients (10.4 vs. 6.9 months, p < 0.001). Conclusions: These analyses show a trend that asymptomatic patients have less severe metastatic brain disease and despite less intensive local BM therapy still have a better outcome (statistically significant for a cohort of HER2-positive patients) than patients who present with symptomatic BM, although a lead time bias of the earlier diagnosis cannot be ruled out. Our analysis is of clinical relevance in the context of potential trials examining the benefit of early detection and treatment of BM.

AB - Background: Brain metastases (BM) have become a major challenge in patients with metastatic breast cancer. Methods: The aim of this analysis was to characterize patients with asymptomatic BM (n = 580) in the overall cohort of 2589 patients with BM from our Brain Metastases in Breast Cancer Network Germany (BMBC) registry. Results: Compared to symptomatic patients, asymptomatic patients were slightly younger at diagnosis (median age: 55.5 vs. 57.0 years, p = 0.01), had a better performance status at diagnosis (Karnofsky index 80-100%: 68.4% vs. 57%, p < 0.001), a lower number of BM (>1 BM: 56% vs. 70%, p = 0.027), and a slightly smaller diameter of BM (median: 1.5 vs. 2.2 cm, p < 0.001). Asymptomatic patients were more likely to have extracranial metastases (86.7% vs. 81.5%, p = 0.003) but were less likely to have leptomeningeal metastasis (6.3% vs. 10.9%, p < 0.001). Asymptomatic patients underwent less intensive BM therapy but had a longer median overall survival (statistically significant for a cohort of HER2-positive patients) compared to symptomatic patients (10.4 vs. 6.9 months, p < 0.001). Conclusions: These analyses show a trend that asymptomatic patients have less severe metastatic brain disease and despite less intensive local BM therapy still have a better outcome (statistically significant for a cohort of HER2-positive patients) than patients who present with symptomatic BM, although a lead time bias of the earlier diagnosis cannot be ruled out. Our analysis is of clinical relevance in the context of potential trials examining the benefit of early detection and treatment of BM.

U2 - 10.3390/cancers12102787

DO - 10.3390/cancers12102787

M3 - SCORING: Journal article

C2 - 32998430

VL - 12

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 10

ER -